Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics, a $4.3B biotech company, is developing VK2735, a weight loss drug candidate in late-stage trials. Bulls cite the massive $100B obesity drug market opportunity, potential acquisition interest, and positive historical stock reactions to data releases. Bears highlight competition from pharma giants Eli Lilly and Novo Nordisk, pipeline risk, and the stock's 40% year-over-year gain. The analyst believes the bull case outweighs the bear case, suggesting Viking could reach $50 if upcoming data proves positive.